AustralieFrV1, PascalFrancis, Corpus, bibRecord, 000953

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Identifieur interne : 000953 ( PascalFrancis/Corpus ); précédent : 000952; suivant : 000954

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Auteurs : A. M. Evens ; S. Choquet ; A. R. Kroll-Desrosiers ; D. Jagadeesh ; S. M. Smith ; F. Morschhauser ; V. Leblond ; R. Roy ; B. Barton ; L. I. Gordon ; M. K. Gandhi ; D. Dierickx ; D. Schiff ; T. M. Habermann ; R. Trappe

Source :

American journal of transplantation : (Print) [ 1600-6135 ] ; 2013.

RBID : Pascal:13-0235169

Descripteurs français

Pascal (Inist)
- Syndrome lymphoprolifératif posttransplantation, Primaire, Système nerveux central, Syndrome lymphoprolifératif, International, Monde, Lymphome, Compte rendu, Etude cas, Rituximab, Pronostic, Immunodépresseur, Immunothérapie, Anticorps monoclonal, Anticancéreux, Immunomodulateur, Traitement, Antigène CD20, Hémopathie maligne lymphoïde.

English descriptors

KwdEn :
- Antineoplastic agent, Case study, Central nervous system, Immunomodulator, Immunosuppressive agent, Immunotherapy, International, Lymphoid neoplasm, Lymphoma, Lymphoproliferative syndrome, Monoclonal antibody, Posttransplant lymphoproliferative disorder, Primary, Prognosis, Report, Rituximab, Treatment, World.

Abstract

We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1600-6135`
A03		`1`		`@0 Am. j. transplant. : (Print)`
A05				`@2 13`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era`
A11	`01`	`1`		`@1 EVENS (A. M.)`
A11	`02`	`1`		`@1 CHOQUET (S.)`
A11	`03`	`1`		`@1 KROLL-DESROSIERS (A. R.)`
A11	`04`	`1`		`@1 JAGADEESH (D.)`
A11	`05`	`1`		`@1 SMITH (S. M.)`
A11	`06`	`1`		`@1 MORSCHHAUSER (F.)`
A11	`07`	`1`		`@1 LEBLOND (V.)`
A11	`08`	`1`		`@1 ROY (R.)`
A11	`09`	`1`		`@1 BARTON (B.)`
A11	`10`	`1`		`@1 GORDON (L. I.)`
A11	`11`	`1`		`@1 GANDHI (M. K.)`
A11	`12`	`1`		`@1 DIERICKX (D.)`
A11	`13`	`1`		`@1 SCHIFF (D.)`
A11	`14`	`1`		`@1 HABERMANN (T. M.)`
A11	`15`	`1`		`@1 TRAPPE (R.)`
A14	`01`			`@1 Division of Hematology/Oncology, The University of Massachusetts Medical School @2 Worcester, MA @3 USA @Z 1 aut. @Z 4 aut.`
A14	`02`			`@1 Hematology, Hospital Pitie-Salpetriere @2 Paris @3 FRA @Z 2 aut. @Z 7 aut.`
A14	`03`			`@1 Ouantitative Health Sciences, The University of Massachusetts @2 Worcester, MA @3 USA @Z 3 aut. @Z 9 aut.`
A14	`04`			`@1 Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals @2 Chicago, IL @3 USA @Z 5 aut.`
A14	`05`			`@1 Hematology, Lille University Hospital @2 Paris @3 FRA @Z 6 aut.`
A14	`06`			`@1 Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University @2 Chicago, IL @3 USA @Z 8 aut. @Z 10 aut.`
A14	`07`			`@1 Princess Alexandra Hospital @2 Brisbane, Old @3 AUS @Z 11 aut.`
A14	`08`			`@1 Department of Hematology, University Hospitals Leuven @2 Leuven @3 BEL @Z 12 aut.`
A14	`09`			`@1 Division of Neuro-Oncology, University of Virginia @2 Charlottesville, VA @3 USA @Z 13 aut.`
A14	`10`			`@1 Division of Hematology, Mayo Clinic @2 Rochester, MN @3 USA @Z 14 aut.`
A14	`11`			`@1 Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel @2 Kiel @3 DEU @Z 15 aut.`
A20				`@1 1512-1522`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 27587 @5 354000503626080160`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 38 ref.`
A47	`01`	`1`		`@0 13-0235169`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 American journal of transplantation : (Print)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.
C02	`01`	`X`		`@0 002B25`
C02	`02`	`X`		`@0 002B19B`
C03	`01`	`X`	`FRE`	`@0 Syndrome lymphoprolifératif posttransplantation @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Posttransplant lymphoproliferative disorder @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Síndrome linfoproliferativo postrasplante @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Primaire @5 02`
C03	`02`	`X`	`ENG`	`@0 Primary @5 02`
C03	`02`	`X`	`SPA`	`@0 Primario @5 02`
C03	`03`	`X`	`FRE`	`@0 Système nerveux central @5 03`
C03	`03`	`X`	`ENG`	`@0 Central nervous system @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso central @5 03`
C03	`04`	`X`	`FRE`	`@0 Syndrome lymphoprolifératif @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Lymphoproliferative syndrome @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Linfoproliferativo síndrome @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 International @5 05`
C03	`05`	`X`	`ENG`	`@0 International @5 05`
C03	`05`	`X`	`SPA`	`@0 Internacional @5 05`
C03	`06`	`X`	`FRE`	`@0 Monde @2 NG @5 06`
C03	`06`	`X`	`ENG`	`@0 World @2 NG @5 06`
C03	`06`	`X`	`SPA`	`@0 Mundo @2 NG @5 06`
C03	`07`	`X`	`FRE`	`@0 Lymphome @5 07`
C03	`07`	`X`	`ENG`	`@0 Lymphoma @5 07`
C03	`07`	`X`	`SPA`	`@0 Linfoma @5 07`
C03	`08`	`X`	`FRE`	`@0 Compte rendu @5 08`
C03	`08`	`X`	`ENG`	`@0 Report @5 08`
C03	`08`	`X`	`SPA`	`@0 Informe @5 08`
C03	`09`	`X`	`FRE`	`@0 Etude cas @5 09`
C03	`09`	`X`	`ENG`	`@0 Case study @5 09`
C03	`09`	`X`	`SPA`	`@0 Estudio caso @5 09`
C03	`10`	`X`	`FRE`	`@0 Rituximab @2 NK @2 FR @5 10`
C03	`10`	`X`	`ENG`	`@0 Rituximab @2 NK @2 FR @5 10`
C03	`10`	`X`	`SPA`	`@0 Rituximab @2 NK @2 FR @5 10`
C03	`11`	`X`	`FRE`	`@0 Pronostic @5 11`
C03	`11`	`X`	`ENG`	`@0 Prognosis @5 11`
C03	`11`	`X`	`SPA`	`@0 Pronóstico @5 11`
C03	`12`	`X`	`FRE`	`@0 Immunodépresseur @5 12`
C03	`12`	`X`	`ENG`	`@0 Immunosuppressive agent @5 12`
C03	`12`	`X`	`SPA`	`@0 Inmunodepresor @5 12`
C03	`13`	`X`	`FRE`	`@0 Immunothérapie @5 13`
C03	`13`	`X`	`ENG`	`@0 Immunotherapy @5 13`
C03	`13`	`X`	`SPA`	`@0 Inmunoterapia @5 13`
C03	`14`	`X`	`FRE`	`@0 Anticorps monoclonal @5 17`
C03	`14`	`X`	`ENG`	`@0 Monoclonal antibody @5 17`
C03	`14`	`X`	`SPA`	`@0 Anticuerpo monoclonal @5 17`
C03	`15`	`X`	`FRE`	`@0 Anticancéreux @5 25`
C03	`15`	`X`	`ENG`	`@0 Antineoplastic agent @5 25`
C03	`15`	`X`	`SPA`	`@0 Anticanceroso @5 25`
C03	`16`	`X`	`FRE`	`@0 Immunomodulateur @5 26`
C03	`16`	`X`	`ENG`	`@0 Immunomodulator @5 26`
C03	`16`	`X`	`SPA`	`@0 Inmunomodulador @5 26`
C03	`17`	`X`	`FRE`	`@0 Traitement @5 27`
C03	`17`	`X`	`ENG`	`@0 Treatment @5 27`
C03	`17`	`X`	`SPA`	`@0 Tratamiento @5 27`
C03	`18`	`X`	`FRE`	`@0 Antigène CD20 @4 INC @5 86`
C03	`19`	`X`	`FRE`	`@0 Hémopathie maligne lymphoïde @4 CD @5 96`
C03	`19`	`X`	`ENG`	`@0 Lymphoid neoplasm @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Hémopathie maligne @2 NM @5 37`
C07	`01`	`X`	`ENG`	`@0 Malignant hemopathy @2 NM @5 37`
C07	`01`	`X`	`SPA`	`@0 Hemopatía maligna @2 NM @5 37`
C07	`02`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`02`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`02`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`03`	`X`	`FRE`	`@0 Anti-CD20 @4 INC @5 87`
N21				`@1 217`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 13-0235169 INIST
ET :	Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
AU :	EVENS (A. M.); CHOQUET (S.); KROLL-DESROSIERS (A. R.); JAGADEESH (D.); SMITH (S. M.); MORSCHHAUSER (F.); LEBLOND (V.); ROY (R.); BARTON (B.); GORDON (L. I.); GANDHI (M. K.); DIERICKX (D.); SCHIFF (D.); HABERMANN (T. M.); TRAPPE (R.)
AF :	Division of Hematology/Oncology, The University of Massachusetts Medical School/Worcester, MA/Etats-Unis (1 aut., 4 aut.); Hematology, Hospital Pitie-Salpetriere/Paris/France (2 aut., 7 aut.); Ouantitative Health Sciences, The University of Massachusetts/Worcester, MA/Etats-Unis (3 aut., 9 aut.); Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals/Chicago, IL/Etats-Unis (5 aut.); Hematology, Lille University Hospital/Paris/France (6 aut.); Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University/Chicago, IL/Etats-Unis (8 aut., 10 aut.); Princess Alexandra Hospital/Brisbane, Old/Australie (11 aut.); Department of Hematology, University Hospitals Leuven/Leuven/Belgique (12 aut.); Division of Neuro-Oncology, University of Virginia/Charlottesville, VA/Etats-Unis (13 aut.); Division of Hematology, Mayo Clinic/Rochester, MN/Etats-Unis (14 aut.); Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel/Kiel/Allemagne (15 aut.)
DT :	Publication en série; Niveau analytique
SO :	American journal of transplantation : (Print); ISSN 1600-6135; Etats-Unis; Da. 2013; Vol. 13; No. 6; Pp. 1512-1522; Bibl. 38 ref.
LA :	Anglais
EA :	We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.
CC :	002B25; 002B19B
FD :	Syndrome lymphoprolifératif posttransplantation; Primaire; Système nerveux central; Syndrome lymphoprolifératif; International; Monde; Lymphome; Compte rendu; Etude cas; Rituximab; Pronostic; Immunodépresseur; Immunothérapie; Anticorps monoclonal; Anticancéreux; Immunomodulateur; Traitement; Antigène CD20; Hémopathie maligne lymphoïde
FG :	Hémopathie maligne; Cancer; Anti-CD20
ED :	Posttransplant lymphoproliferative disorder; Primary; Central nervous system; Lymphoproliferative syndrome; International; World; Lymphoma; Report; Case study; Rituximab; Prognosis; Immunosuppressive agent; Immunotherapy; Monoclonal antibody; Antineoplastic agent; Immunomodulator; Treatment; Lymphoid neoplasm
EG :	Malignant hemopathy; Cancer
SD :	Síndrome linfoproliferativo postrasplante; Primario; Sistema nervioso central; Linfoproliferativo síndrome; Internacional; Mundo; Linfoma; Informe; Estudio caso; Rituximab; Pronóstico; Inmunodepresor; Inmunoterapia; Anticuerpo monoclonal; Anticanceroso; Inmunomodulador; Tratamiento
LO :	INIST-27587.354000503626080160
ID :	13-0235169

Links to Exploration step

Pascal:13-0235169

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era</title>
<author><name sortKey="Evens, A M" sort="Evens, A M" uniqKey="Evens A" first="A. M." last="Evens">A. M. Evens</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Choquet, S" sort="Choquet, S" uniqKey="Choquet S" first="S." last="Choquet">S. Choquet</name>
<affiliation><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kroll Desrosiers, A R" sort="Kroll Desrosiers, A R" uniqKey="Kroll Desrosiers A" first="A. R." last="Kroll-Desrosiers">A. R. Kroll-Desrosiers</name>
<affiliation><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jagadeesh, D" sort="Jagadeesh, D" uniqKey="Jagadeesh D" first="D." last="Jagadeesh">D. Jagadeesh</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Smith, S M" sort="Smith, S M" uniqKey="Smith S" first="S. M." last="Smith">S. M. Smith</name>
<affiliation><inist:fA14 i1="04"><s1>Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F." last="Morschhauser">F. Morschhauser</name>
<affiliation><inist:fA14 i1="05"><s1>Hematology, Lille University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leblond, V" sort="Leblond, V" uniqKey="Leblond V" first="V." last="Leblond">V. Leblond</name>
<affiliation><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Roy, R" sort="Roy, R" uniqKey="Roy R" first="R." last="Roy">R. Roy</name>
<affiliation><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Barton, B" sort="Barton, B" uniqKey="Barton B" first="B." last="Barton">B. Barton</name>
<affiliation><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gordon, L I" sort="Gordon, L I" uniqKey="Gordon L" first="L. I." last="Gordon">L. I. Gordon</name>
<affiliation><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gandhi, M K" sort="Gandhi, M K" uniqKey="Gandhi M" first="M. K." last="Gandhi">M. K. Gandhi</name>
<affiliation><inist:fA14 i1="07"><s1>Princess Alexandra Hospital</s1>
<s2>Brisbane, Old</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dierickx, D" sort="Dierickx, D" uniqKey="Dierickx D" first="D." last="Dierickx">D. Dierickx</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Hematology, University Hospitals Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schiff, D" sort="Schiff, D" uniqKey="Schiff D" first="D." last="Schiff">D. Schiff</name>
<affiliation><inist:fA14 i1="09"><s1>Division of Neuro-Oncology, University of Virginia</s1>
<s2>Charlottesville, VA</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Habermann, T M" sort="Habermann, T M" uniqKey="Habermann T" first="T. M." last="Habermann">T. M. Habermann</name>
<affiliation><inist:fA14 i1="10"><s1>Division of Hematology, Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trappe, R" sort="Trappe, R" uniqKey="Trappe R" first="R." last="Trappe">R. Trappe</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0235169</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0235169 INIST</idno>
<idno type="RBID">Pascal:13-0235169</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000953</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era</title>
<author><name sortKey="Evens, A M" sort="Evens, A M" uniqKey="Evens A" first="A. M." last="Evens">A. M. Evens</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Choquet, S" sort="Choquet, S" uniqKey="Choquet S" first="S." last="Choquet">S. Choquet</name>
<affiliation><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kroll Desrosiers, A R" sort="Kroll Desrosiers, A R" uniqKey="Kroll Desrosiers A" first="A. R." last="Kroll-Desrosiers">A. R. Kroll-Desrosiers</name>
<affiliation><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jagadeesh, D" sort="Jagadeesh, D" uniqKey="Jagadeesh D" first="D." last="Jagadeesh">D. Jagadeesh</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Smith, S M" sort="Smith, S M" uniqKey="Smith S" first="S. M." last="Smith">S. M. Smith</name>
<affiliation><inist:fA14 i1="04"><s1>Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F." last="Morschhauser">F. Morschhauser</name>
<affiliation><inist:fA14 i1="05"><s1>Hematology, Lille University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leblond, V" sort="Leblond, V" uniqKey="Leblond V" first="V." last="Leblond">V. Leblond</name>
<affiliation><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Roy, R" sort="Roy, R" uniqKey="Roy R" first="R." last="Roy">R. Roy</name>
<affiliation><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Barton, B" sort="Barton, B" uniqKey="Barton B" first="B." last="Barton">B. Barton</name>
<affiliation><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gordon, L I" sort="Gordon, L I" uniqKey="Gordon L" first="L. I." last="Gordon">L. I. Gordon</name>
<affiliation><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gandhi, M K" sort="Gandhi, M K" uniqKey="Gandhi M" first="M. K." last="Gandhi">M. K. Gandhi</name>
<affiliation><inist:fA14 i1="07"><s1>Princess Alexandra Hospital</s1>
<s2>Brisbane, Old</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dierickx, D" sort="Dierickx, D" uniqKey="Dierickx D" first="D." last="Dierickx">D. Dierickx</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Hematology, University Hospitals Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schiff, D" sort="Schiff, D" uniqKey="Schiff D" first="D." last="Schiff">D. Schiff</name>
<affiliation><inist:fA14 i1="09"><s1>Division of Neuro-Oncology, University of Virginia</s1>
<s2>Charlottesville, VA</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Habermann, T M" sort="Habermann, T M" uniqKey="Habermann T" first="T. M." last="Habermann">T. M. Habermann</name>
<affiliation><inist:fA14 i1="10"><s1>Division of Hematology, Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trappe, R" sort="Trappe, R" uniqKey="Trappe R" first="R." last="Trappe">R. Trappe</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">American journal of transplantation : (Print)</title>
<title level="j" type="abbreviated">Am. j. transplant. : (Print)</title>
<idno type="ISSN">1600-6135</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">American journal of transplantation : (Print)</title>
<title level="j" type="abbreviated">Am. j. transplant. : (Print)</title>
<idno type="ISSN">1600-6135</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Case study</term>
<term>Central nervous system</term>
<term>Immunomodulator</term>
<term>Immunosuppressive agent</term>
<term>Immunotherapy</term>
<term>International</term>
<term>Lymphoid neoplasm</term>
<term>Lymphoma</term>
<term>Lymphoproliferative syndrome</term>
<term>Monoclonal antibody</term>
<term>Posttransplant lymphoproliferative disorder</term>
<term>Primary</term>
<term>Prognosis</term>
<term>Report</term>
<term>Rituximab</term>
<term>Treatment</term>
<term>World</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome lymphoprolifératif posttransplantation</term>
<term>Primaire</term>
<term>Système nerveux central</term>
<term>Syndrome lymphoprolifératif</term>
<term>International</term>
<term>Monde</term>
<term>Lymphome</term>
<term>Compte rendu</term>
<term>Etude cas</term>
<term>Rituximab</term>
<term>Pronostic</term>
<term>Immunodépresseur</term>
<term>Immunothérapie</term>
<term>Anticorps monoclonal</term>
<term>Anticancéreux</term>
<term>Immunomodulateur</term>
<term>Traitement</term>
<term>Antigène CD20</term>
<term>Hémopathie maligne lymphoïde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1600-6135</s0>
</fA01>
<fA03 i2="1"><s0>Am. j. transplant. : (Print)</s0>
</fA03>
<fA05><s2>13</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>EVENS (A. M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CHOQUET (S.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KROLL-DESROSIERS (A. R.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JAGADEESH (D.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SMITH (S. M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MORSCHHAUSER (F.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LEBLOND (V.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ROY (R.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>BARTON (B.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>GORDON (L. I.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>GANDHI (M. K.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>DIERICKX (D.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>SCHIFF (D.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>HABERMANN (T. M.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>TRAPPE (R.)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Hematology, Lille University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Princess Alexandra Hospital</s1>
<s2>Brisbane, Old</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Hematology, University Hospitals Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Division of Neuro-Oncology, University of Virginia</s1>
<s2>Charlottesville, VA</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Division of Hematology, Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA20><s1>1512-1522</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27587</s2>
<s5>354000503626080160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>38 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0235169</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>American journal of transplantation : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B25</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B19B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Syndrome lymphoprolifératif posttransplantation</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Posttransplant lymphoproliferative disorder</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Síndrome linfoproliferativo postrasplante</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Primaire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Primary</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Primario</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Syndrome lymphoprolifératif</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>International</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>International</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Internacional</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Monde</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>World</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Mundo</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Lymphome</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Lymphoma</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Linfoma</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Compte rendu</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Report</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Informe</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Case study</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Rituximab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Rituximab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Rituximab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Immunodépresseur</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Immunosuppressive agent</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Inmunodepresor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Immunothérapie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Immunotherapy</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Inmunoterapia</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Anticorps monoclonal</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Monoclonal antibody</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>25</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Immunomodulateur</s0>
<s5>26</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Immunomodulator</s0>
<s5>26</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Inmunomodulador</s0>
<s5>26</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Traitement</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Treatment</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>27</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Antigène CD20</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Hémopathie maligne lymphoïde</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Lymphoid neoplasm</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Anti-CD20</s0>
<s4>INC</s4>
<s5>87</s5>
</fC07>
<fN21><s1>217</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 13-0235169 INIST</NO>
<ET>Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era</ET>
<AU>EVENS (A. M.); CHOQUET (S.); KROLL-DESROSIERS (A. R.); JAGADEESH (D.); SMITH (S. M.); MORSCHHAUSER (F.); LEBLOND (V.); ROY (R.); BARTON (B.); GORDON (L. I.); GANDHI (M. K.); DIERICKX (D.); SCHIFF (D.); HABERMANN (T. M.); TRAPPE (R.)</AU>
<AF>Division of Hematology/Oncology, The University of Massachusetts Medical School/Worcester, MA/Etats-Unis (1 aut., 4 aut.); Hematology, Hospital Pitie-Salpetriere/Paris/France (2 aut., 7 aut.); Ouantitative Health Sciences, The University of Massachusetts/Worcester, MA/Etats-Unis (3 aut., 9 aut.); Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals/Chicago, IL/Etats-Unis (5 aut.); Hematology, Lille University Hospital/Paris/France (6 aut.); Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University/Chicago, IL/Etats-Unis (8 aut., 10 aut.); Princess Alexandra Hospital/Brisbane, Old/Australie (11 aut.); Department of Hematology, University Hospitals Leuven/Leuven/Belgique (12 aut.); Division of Neuro-Oncology, University of Virginia/Charlottesville, VA/Etats-Unis (13 aut.); Division of Hematology, Mayo Clinic/Rochester, MN/Etats-Unis (14 aut.); Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel/Kiel/Allemagne (15 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>American journal of transplantation : (Print); ISSN 1600-6135; Etats-Unis; Da. 2013; Vol. 13; No. 6; Pp. 1512-1522; Bibl. 38 ref.</SO>
<LA>Anglais</LA>
<EA>We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.</EA>
<CC>002B25; 002B19B</CC>
<FD>Syndrome lymphoprolifératif posttransplantation; Primaire; Système nerveux central; Syndrome lymphoprolifératif; International; Monde; Lymphome; Compte rendu; Etude cas; Rituximab; Pronostic; Immunodépresseur; Immunothérapie; Anticorps monoclonal; Anticancéreux; Immunomodulateur; Traitement; Antigène CD20; Hémopathie maligne lymphoïde</FD>
<FG>Hémopathie maligne; Cancer; Anti-CD20</FG>
<ED>Posttransplant lymphoproliferative disorder; Primary; Central nervous system; Lymphoproliferative syndrome; International; World; Lymphoma; Report; Case study; Rituximab; Prognosis; Immunosuppressive agent; Immunotherapy; Monoclonal antibody; Antineoplastic agent; Immunomodulator; Treatment; Lymphoid neoplasm</ED>
<EG>Malignant hemopathy; Cancer</EG>
<SD>Síndrome linfoproliferativo postrasplante; Primario; Sistema nervioso central; Linfoproliferativo síndrome; Internacional; Mundo; Linfoma; Informe; Estudio caso; Rituximab; Pronóstico; Inmunodepresor; Inmunoterapia; Anticuerpo monoclonal; Anticanceroso; Inmunomodulador; Tratamiento</SD>
<LO>INIST-27587.354000503626080160</LO>
<ID>13-0235169</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000953 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000953 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:13-0235169
   |texte=   Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri